| Symbol |
Name |
|
ABL1
|
ABL proto-oncogene 1, non-receptor tyrosine kinase
|
|
ACAN
|
aggrecan
|
|
AHR
|
aryl hydrocarbon receptor
|
|
AHRR
|
aryl-hydrocarbon receptor repressor
|
|
AURKA
|
aurora kinase A
|
|
AXIN2
|
axin 2
|
|
CCL2
|
chemokine (C-C motif) ligand 2
|
|
CCN2
|
cellular communication network factor 2
|
|
CDKN1A
|
cyclin-dependent kinase inhibitor 1A (p21, Cip1)
|
|
CDKN1B
|
cyclin-dependent kinase inhibitor 1B (p27, Kip1)
|
|
CDKN2B
|
cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4)
|
|
CDKN2C
|
cyclin-dependent kinase inhibitor 2C (p18, inhibits CDK4)
|
|
CIC
|
capicua transcriptional repressor
|
|
CTNNB1
|
catenin (cadherin-associated protein), beta 1, 88kDa
|
|
DCN
|
decorin
|
|
EGF
|
epidermal growth factor
|
|
ERBB2
|
erb-b2 receptor tyrosine kinase 2
|
|
EREG
|
epiregulin
|
|
FOLH1
|
folate hydrolase (prostate-specific membrane antigen) 1
|
|
FOXO4
|
forkhead box O4
|
|
GSTM1
|
glutathione S-transferase mu 1
|
|
HRAS
|
Harvey rat sarcoma viral oncogene homolog
|
|
IGF2
|
insulin-like growth factor 2
|
|
LHCGR
|
luteinizing hormone/choriogonadotropin receptor
|
|
MDM2
|
MDM2 proto-oncogene, E3 ubiquitin protein ligase
|
|
MED12
|
mediator complex subunit 12
|
|
MEN1
|
multiple endocrine neoplasia I
|
|
MLH1
|
mutL homolog 1
|
|
MMP9
|
matrix metallopeptidase 9
|
|
MTOR
|
mechanistic target of rapamycin (serine/threonine kinase)
|
|
MYC
|
v-myc avian myelocytomatosis viral oncogene homolog
|
|
NCOA2
|
nuclear receptor coactivator 2
|
|
P4HA2
|
prolyl 4-hydroxylase, alpha polypeptide II
|
|
RPS6
|
ribosomal protein S6
|
|
S100A7
|
S100 calcium binding protein A7
|
|
SPARC
|
secreted protein, acidic, cysteine-rich (osteonectin)
|
|
STAT6
|
signal transducer and activator of transcription 6, interleukin-4 induced
|
|
TBCK
|
TBC1 domain containing kinase
|
|
TIMP1
|
TIMP metallopeptidase inhibitor 1
|
|
TIMP2
|
TIMP metallopeptidase inhibitor 2
|
|
TP53
|
tumor protein p53
|
|
TSC1
|
tuberous sclerosis 1
|
|
TSC2
|
tuberous sclerosis 2
|
|
VCAN
|
versican
|
